Skip to main content
SpringerLink
Log in

Anti-Integrin-Antikörper

Wie schneidet Vedolizumab bei CED-Patienten im klinischen Alltag ab?

  • journal club
  • Published:
Gastro-News Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

1

Literatur

  • Lenti MV et al. A real-world, long-term experience on effectiveness and safety of vedolizumab in adult patients with inflammatory bowel disease: The Cross Pennine study Dig Liver Dis 2018;50:1299–1304

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Renatatstraße 50, 80639, München, Deutschland

    Hermann S. Füeßl (Internist — Gastroenterologe, Privatpraxis für Integrative Innere Medizin)

Authors
  1. Hermann S. Füeßl
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hermann S. Füeßl.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Füeßl, H.S. Wie schneidet Vedolizumab bei CED-Patienten im klinischen Alltag ab?. Gastro-News 6, 25–26 (2019). https://doi.org/10.1007/s15036-019-0564-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15036-019-0564-x

Search

Navigation